Verrica Pharmaceuticals Inc. filed its quarterly report on Form 10-Q with the SEC on November 13, 2026, covering the fiscal quarter and nine-month period ended September 30, 2026, reporting a net loss of $35,242 thousand for the nine months ended September 30, 2026.

Key Highlights

  • Nine-month net loss: The company reported a net loss of $35,242 thousand for the nine months ended September 30, 2026, compared to a net loss of $9,812 thousand for the same period in 2025.
  • Third-quarter net loss: Net loss for the three months ended September 30, 2026 was $12,407 thousand, versus $274 thousand for the same quarter in 2025.
  • Product revenue growth: Product revenue, net, was $15,080 thousand for the nine months ended September 30, 2026, up from $11,563 thousand in the same prior-year period.
  • Accumulated deficit: The accumulated deficit reached $360,155 thousand as of September 30, 2026, compared to $324,913 thousand as of December 31, 2025.
  • Stockholders' deficit: Total stockholders' deficit was $(5,974) thousand as of September 30, 2026, compared to stockholders' equity of $24,743 thousand as of December 31, 2025.
  • New term loans: Term loans, net, related party of $11,636 thousand appeared on the balance sheet as of September 30, 2026, with no comparable balance as of December 31, 2025.
  • Legal settlement liability: A legal settlement liability of $4,000 thousand was recorded as of September 30, 2026, with no comparable balance as of December 31, 2025.

Verrica Pharmaceuticals Financial Results: Q3 and Nine-Month Period, 2026

According to the filing, Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) reported total revenue of $6,914 thousand for the three months ended September 30, 2026, down from $14,344 thousand in the same quarter of 2025. For the nine months ended September 30, 2026, total revenue was $17,799 thousand, compared to $30,485 thousand for the nine months ended September 30, 2025. The company disclosed that license and collaboration revenue declined substantially, from $10,737 thousand in Q3 2025 to $1,217 thousand in Q3 2026, and from $18,922 thousand for the first nine months of 2025 to $2,719 thousand for the same period in 2026.

Total operating expenses rose to $19,081 thousand for the three months ended September 30, 2026, from $12,717 thousand in the same quarter a year earlier. For the nine-month period, total operating expenses were $52,778 thousand versus $35,478 thousand in 2025. The company disclosed that research and development expenses increased to $17,471 thousand for the nine months ended September 30, 2026, from $6,335 thousand for the nine months ended September 30, 2025. Selling, general and administrative expenses were $30,694 thousand for the nine months ended September 30, 2026, compared to $27,103 thousand in the prior-year period. The filing also disclosed a legal settlement charge, net of insurance recovery, of $1,698 thousand for the nine months ended September 30, 2026.

The company's balance sheet reflected total assets of $39,861 thousand and total liabilities of $45,835 thousand as of September 30, 2026. Cash declined to $14,394 thousand from $30,147 thousand at December 31, 2025. The filing noted a new derivative liability of $556 thousand and an R&D funding liability of $10,940 thousand as of September 30, 2026. As of November 5, 2026, the registrant had 17,178,786 shares of common stock outstanding. Net loss per share, basic and diluted, was $(0.58) for Q3 2026 and $(1.65) for the nine months ended September 30, 2026.

What Was Disclosed

Verrica Pharmaceuticals filed its Form 10-Q for the quarter ended September 30, 2026, disclosing a nine-month net loss of $35,242 thousand, a stockholders' deficit of $(5,974) thousand, new related-party term loans of $11,636 thousand, and a legal settlement liability of $4,000 thousand.